Table 3.
HLA DSAs and kidney allograft function evolution in belatacept and control groups
| Treatment |
Belatacept |
Control |
||||
|---|---|---|---|---|---|---|
| Variables | Before belatacept | 12 months after belatacept | P-value | Before transplantation | 12 months after transplantation | P-value |
| Immunological variables | ||||||
| Recipient, n | 12 | 9 | 20 | 19 | – | |
| HLA DSA Class 1 | ||||||
| n (%) | 2 (17) | 4 (44) | 0.12 | 8 (40) | 4 (21) | 0.30 |
| MFI max, median (IQR) | 2878 (2006–3750) | 1884 (1059–2661) | 1.00 | 832 (520–1324) | 1921 (870–4175) | – |
| MFI sum, median (IQR) | 3875 (3750–4000) | 2137 (1592–2661) | 1.00 | 832 (520–1805) | 2211 (1015–4175) | – |
| HLA DSA Class 2 | ||||||
| n (%) | 6 (50) | 4 (44) | 1.00 | 5 (25) | 4 (21) | 1.00 |
| MFI max, median (IQR) | 2205 (1309–10 349) | 2835 (2168–4060) | 1.00 | 849 (620–1378) | 2617 (223–4574) | 0.25 |
| MFI sum, median (IQR) | 3038 (1440–11 291) | 4971 (2501–5195) | 1.00 | 1315 (620–1969) | 2773 (223–5816) | 0.25 |
| Kidney allograft function (conversion) | ||||||
| Recipient, n | 12 | 9 | ||||
| eGFR, median (IQR), mL/min/1.73 m2 | 13 (9–19) | 18 (15–27) | 0.009 | – | – | – |
| Proteinuria/creatininuria ratio, median (IQR) | 37 (12–57) | 30 (15–63) | 0.22 | – | – | – |